SBIR/STTR Research Award

Preferential Display (PD) based PROTECT system

Award identifier 7e1aff8ff9ea88f7a638654ebe819723d3869e0828fa08f513ee9390d3f9b7c8Awarding agency Department of Defense · Air Force

Award amount

$99,998

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Air Force
Recipient company
GENEXPRESS INFORMATICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Exposure of humans to chemical or biological warfare agents has been demonstrate to be detected within hours of contact by measuring gene expression levels (profiles) on a genomic scale using microarray chips. While this technology has been shown to bedeployable in the field, the human genomics databases are insufficient to diagnose which chemical or pathogen a person has been exposed to.GeneXpress Informatics, Inc. (GXI) and Dr. J.P.,Chambers of University of Texas at San Antonio propose to develop a differential gene display technology, called Preferential Display (PD), which will provide a simplified, cost-effective and efficientmethod to identify induced transcripts associated with military personnel exposure to chemical or biological warfare agents. By identifying these chemical/biowarfare agent induced transcripts, GXI intends to provide an unprecedented number of leadsequences for DNA microarray monitoring applications. In Phase I, GXI and Dr. Chambers proposes isolate and identify a preliminary set of gene sequences from a cell line which have been challenged by a chemical or biowarfare agent. The Phase II programwill result in a fully automated PROTECT system for use in identifying and isolating biosignataure sequence databases from human test subjects. The PD technology offers a revolutionary technology to isolate and identify gene expression profiles of diseased versus normal tissues for use in developing microarray chips for medical diagnosis and monitoring of infectious diseases. The databasesgenerated will have a wide commercial market as new drugs or drug targets.

Technology keywords

Not reported

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.